Cancer survivors face a 14% higher risk of developing entirely new cancers (secondary malignancies) compared to the general population, and they account for nearly 19% of all cancer diagnoses in the U.S. Oncology Advanced Practice Providers (APPs) highlight that past treatments, especially radiation and certain chemotherapies like alkylating agents, platinum-based drugs, anthracycline topoisomerase II inhibitors, and even targeted therapies, can contribute to long-term risk.
News
